Ilimaquinone and ethylsmenoquinone activate the p53 pathway by promoting the phosphorylation and accumulation of the p53 protein, in turn inhibiting the proliferation of colon cancer cells by inducing G2/M cell cycle arrest, apoptosis and autophagy. Here, TP53 is linked to malignant colon neoplasm.